Collegium Pharmaceutical, Inc. is undervalued and offers significant growth potential with its pain portfolio and ADHD treatments. The company’s acquisition of BioDelivery Sciences International and management team’s track record position it for success. Trading at under 5x EV/EBITDA, COLL has a reasonable upside to $60 per share.

Taysha Gene Therapies Inc. receives a ‘Market Perform’ rating for its Rett Syndrome Therapy by JMP Securities.

Viking Therapeutics, Inc. faces execution and competitive challenges, resulting in a 5.96% stock depreciation since a bullish thesis in February 2025. However, the company’s obesity drug candidate VK2735 and dual GLP-1/GIP mechanism still hold promise in the market.

Read more at Yahoo Finance: Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory